Efficacy and Safety of Empagliflozin Monotherapy for 52 Weeks in Japanese Patients with Type 2 Diabetes: A Randomized, Double-Blind, Parallel-Group Study

Conclusion Empagliflozin monotherapy for 52 weeks led to sustained reductions in HbA1c, FPG, weight and BP and was well tolerated in Japanese patients with T2DM. Funding Boehringer Ingelheim and Eli Lilly and Company.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research